(CercleFinance.com) – Novacyt shares are sought Wednesday morning on the Paris Stock Exchange after the green light granted by the British authorities to a new test developed by the specialist in clinical diagnosis.
Shortly before 10:00 a.m., the stock gained 7.2% in high volumes already representing almost double their daily average for the last four sessions. At the same time, the CAC Mid & Small index took 0.2%.
The Franco-British company announced this morning the approval by the British Health Security Agency (CTDA) of its PROmate Covid-19 1 test
Embarrassed.
This test, designed to detect a SARS-CoV-2 target within the ORF1ab gene, is believed to eliminate the need for complex, manual or automated extraction solutions to improve laboratory workflow and reduce costs .
This is the third real-time PCR product and the company’s fourth product to be added to the registry of approved products of the
CTDA.
‘Following the validation in the UK under CTDA legislation of a number of key products in our Covid-19 portfolio over the past six months, we are well placed to continue to meet the needs of our customers. in terms of Covid-19 tests in the United Kingdom”, commented David Allmond, the group’s CEO.
The company also announced that its PathFlow rapid self-test, a saliva test against Covid that can diagnose symptomatic and asymptomatic individuals in about 15 minutes, has received CE marking.